Drug intelligence / Profile preview

JLC062

Development stage: Preclinical
Lead developer: Jecho Laboratories
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

JLC062 is an investigational bispecific antibody-drug conjugate (ADC) developed by Jecho Laboratories. It is designed to simultaneously target B7-H3 (CD276) and PD-L1 (CD274), two proteins frequently overexpressed in various solid tumors and associated with immune evasion. By dual-targeting these antigens, JLC062 aims to deliver a potent cytotoxic payload directly to cancer cells, enhancing specificity and potentially overcoming resistance mechanisms associated with single-antigen targeting. The drug is currently in the IND-enabling stage of development for the treatment of solid tumors.

Other names: B7H3/PD-L1 ADC

Targets

B7-H3CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on JLC062.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JLC062.

Explore the full profile